{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018793","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.625050+00:00","generated_at":"2026-06-15T13:24:15.786346+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara posts Q1 net loss of $74.8M; R&D head and CTO to depart in May/June","bullets":["Net loss of $74.8M ($0.72/sh) vs $88.1M ($0.87/sh) in Q1 2022; cash $205.4M, runway into Q2 2024.","Jakob Dupont (EVP Global R&D) resigns effective May 12, 2023; Charlene Banard (CTO) departs June 9, 2023.","Tab-cel BLA discussions with FDA continue; label expansion data expected Q4 2023.","ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.","ATA3219 IND filing for B-cell malignancies anticipated end of Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018793","json":"https://secwatch.observer/filing/0000950170-23-018793.json","markdown":"https://secwatch.observer/filing/0000950170-23-018793.md","text":"https://secwatch.observer/filing/0000950170-23-018793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/atra-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:24:15.786346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"305e3ac62d9607d0073f4d5e608f8ee8f0d42396","claim":"Atara Biotherapeutics, Inc. reported the first quarter 2023 results: net income net losses of $74.8 million, EPS $0.72 per share.","evidence_excerpt":"Atara reported net losses of $74.8 million, or $0.72 per share for the first quarter 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2023"},{"label":"Net income","value":"net losses of $74.8 million"},{"label":"EPS","value":"$0.72 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"20b0200f8f","claim":"Charlene Banard departed as Executive Vice President, Chief Technical Officer at Atara Biotherapeutics, Inc..","evidence_excerpt":"Charlene Banard, the Company’s Executive Vice President, Chief Technical Officer, will depart the Company effective as of June 9, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"Executive Vice President, Chief Technical Officer"}],"fact_type":"executive_change"},{"claim_id":"c15d80f18b","claim":"Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..","evidence_excerpt":"Jakob Dupont, M.D., the Company’s Executive Vice President, Global Head of Research and Development, on May 5, 2023, notified the Company of his intention to resign from the Company effective as of May 12, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Global Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}